Home Browse Update Summary

This process involves analyzing complex genetic data and may take a moment.

Return Search

PDX ID	275R
Host Strain(and Source)	NSG Source: Monash University
Host Strain Immune system Humanized	NO
Host Type	Testosterone supplemented
Graft Site	Subcutaneous
Current Generation (* indicates number of generations grown in Castrate host)	18
Average PDX Generation Time (days +/- SEM)	99 ± 9
Tumour preparation	Tumor solid
Tumour Characterization Technology	Histology, IHC, STR profiling, targeted DNA sequencing, RNAseq
Tumour confirmed not to be of Mouse/EBV origin	Yes; negative for CD45 and/or positive for human CK8/18 and/or human mitochondria by IHC
Passage QA performed	Routine QA every 2-3 passages
Associated meta data
PDX model availability	Yes (fixed, frozen)
Governance restriction for distribution	Available to investigators with appropriate ethics approvals, approved EOI from MURAL committee, and material transfer agreements
Pubmed ID	34413304

This heatmap displays the call type of curated CNVs in the presented samples.

This heatmap displays the call type of CNVs in commonly occurred samples.

This table displays curated CNVs

PDX ID	Gene Symbol	CNV Log2	CNV Copy	CNV Call	Experiments name	Platform	Reference genome
275R	CHD7	0.876	3.671	Gain	MURAL Prostate Cancer PDX collection	Targeted GARVAN Panel	hg19
275R	CHD7	0.549	2.926	Gain	MURAL Prostate Cancer PDX collection	Targeted GARVAN Panel	hg19
275R	MYC	0.526	2.880	Gain	MURAL Prostate Cancer PDX collection	Targeted GARVAN Panel	hg19
275R	RB1	-0.931	1.049	Loss	MURAL Prostate Cancer PDX collection	Targeted GARVAN Panel	hg19
275R	TP53	-1.024	0.984	Loss	MURAL Prostate Cancer PDX collection	Targeted GARVAN Panel	hg19
275R	TP53	-0.792	1.155	Loss	MURAL Prostate Cancer PDX collection	Targeted GARVAN Panel	hg19

Sample Number	275R
Sample Site	Prostate
Sample source	Radical prostatectomy
Pathology Tumour Diagnosis	Adenocarcinoma
Gleason Score	7
Primary Gleason Score	4
Secondary Gleason Score	3
Tertiary Gleason Score	None
ISUP Grade Group	3
Tumour Grade	pT3bN0
D'Amico Risk Classification	8
Tumour Volume (in cc)	3.2
Treatment Prior to Specimen Collection	None

Patient Number	275
Sex	Male
Diagnosis	Prostate Cancer
PSA at diagnosis (ng/mL)	45
Consent to share data	Yes, subject to ethical review

Patient Tumour Collection (Current Model)
Tumour sample ID	275R
Patient Age (binned in 5 year age groups)	65-69

This heatmap displays the mutations of curated sequence variants.

This table displays curated sequence variants

PDX ID	Gene Symbol	Total Read Depth	Alternate Frequency	Consequence	Exon	GnomAD AF	CADD PHRED score	ClinVar significance	Platform	Experiments Name	Reference	Library Type	Instrument Type
275R	TH	145	0.54	Missense variant	'4/14	7.90E-05	21.3	Uncertain significance	Targeted GARVAN Panel	MURAL Prostate Cancer PDX collection	hg19	paired	Illumina HiSeq 2500
275R	AKT1	1657	0.49	Missense variant	'10/13	.	29	-	Targeted GARVAN Panel	MURAL Prostate Cancer PDX collection	hg19	paired	Illumina HiSeq 2500
275R	MITF	559	0.48	Missense variant	'9/10	1.63E-05	31	-	Targeted GARVAN Panel	MURAL Prostate Cancer PDX collection	hg19	paired	Illumina HiSeq 2500
275R	BRCA1	988	0.47	Missense variant	'10/24	0.0002358	12.77	Benign	Targeted GARVAN Panel	MURAL Prostate Cancer PDX collection	hg19	paired	Illumina HiSeq 2500
275R	ZNF717	33	0.36	Stop lost	'5/5	.	0.964	-	Targeted GARVAN Panel	MURAL Prostate Cancer PDX collection	hg19	paired	Illumina HiSeq 2500
275R	ZNF717	33	0.36	Stop lost	'5/5	.	0.964	-	Targeted GARVAN Panel	MURAL Prostate Cancer PDX collection	hg19	paired	Illumina HiSeq 2500
275R	ZNF717	60	0.32	Stop gained	'5/5	.	23.7	-	Targeted GARVAN Panel	MURAL Prostate Cancer PDX collection	hg19	paired	Illumina HiSeq 2500
275R	ZNF717	60	0.32	Stop gained	'5/5	.	23.7	-	Targeted GARVAN Panel	MURAL Prostate Cancer PDX collection	hg19	paired	Illumina HiSeq 2500

No information in Drug dosing Table